![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Ampio Pharmaceuticals to Test Investigational Pain Med as COVID-19 Treatment
Ampio Pharmaceuticals to Test Investigational Pain Med as COVID-19 Treatment
![Vaccine needle](https://www.fdanews.com/ext/resources/test/Drug-Images4/Vaccine-needle-bottle.gif?t=1596243581&width=430)
Ampio Pharmaceuticals said it will conduct a phase 1 clinical trial to test its investigational pain treatment Ampion (aspartyl-alanyl diketopiperazine) as a treatment for COVID-19 patients.
The company said it believes the nonsteroidal anti-inflammatory drug may help ease inflammation and improve patient outcomes.
Ampion is currently being developed for the treatment of pain due to osteoarthritis of the knee.
Upcoming Events
-
18Jul
-
21Oct